Skip to main content
. 2020 Sep 4;2020:7083149. doi: 10.1155/2020/7083149

Table 3.

Toxicity and survival outcomes according to elective nodal irradiation status.

Outcome ENI (N = 323) IFRT (N = 323) P value
Acute grade 3-4 hematologic toxicity, n (%)
 Leukopenia 51 (15.7) 32 (9.9) 0.012
 Anemia 23 (7.1) 14 (4.3) 0.14
 Thrombocytopenia 41 (12.7) 30 (9.3) 0.32

Acute grade 3 nonhematologic toxicity, n (%)
 Nausea-vomiting 109 (33.7) 67 (20.7) 0.006
 Esophagitis 49 (15.2) 29 (9.0) 0.003
 Pneumonitis 47 (14.5) 27 (8.4) 0.002
 Peripheric neuropathy 10 (3.1) 11 (3.4) 0.76
 Pericarditis 5 (1.5) 2 (0.6) 0.25

Late grade 3-4 toxicity
 Lung 12 (3.7) 9 (2.8) 0.34
 Esophagus 15 (4.6) 8 (2.5) 0.038
 Heart 5 (1.5) 3 (0.9) 0.78
 Major vessels 3 (0.9) 2 (0.6) 0.64

Late grade 5 toxicity, n (%) 6 (1.8) 4 (1.2) 0.73
 Radiation pneumonitis 2 (0.6) 1 (0.3)
 Tracheoesophageal fistula 2 (0.6) 1 (0.3)
 Bronchopleural fistula 1 (0.3) 1 (0.3)
 Aortic blow-out 1 (0.3) 1 (0.3)

Hospitalization, n (%) 58 (18.0) 28 (8.6) <0.001

PFS
 Median, mo 11.7 (10.8–12.6) 11.2 (10.2–12.4) 0.57
 5-years (%) 12.1 11.6
 10 years (%) 6.2 5.2

LRPFS
 Median, mo 15.3 (14.3–16.3) 15.1 (14.1–16.1) 0.52
 5-years (%) 13.5 13.3
 10 years (%) 7.2 5.8

OS
 Median, mo 25.2 (23.5–26.3) 24.6 (22.6)-26.6 0.69
 5-year (%) 22.2 21.2
 10 year (%) 11.9 11.1

5-year in-field failure, n (%)
 Local 127 (39.3) 125 (38.7) 0.79
 Regional 64 (19.8) 59 (18.3) 0.44
 Local + regional 57 (17.6) 61 (18.9) 0.56

Isolated ENF
 5-years (%) 11 (3.4) 14 (4.3) 0.52
 10 years (%) 16 (4.9) 19 (5.9) 0.71

ENI: elective nodal irradiation; IFRT: involved-field radiotherapy; PFS: progression-free survival; LRPFS: locoregional progression-free survival; OS: overall survival; ENF: elective nodal failure.